ArticleCancers2022
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04354701 (The COVID-19 and Cancer Consortium), which is not on this map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The COVID-19 and Cancer Consortium (CCC19) Registry
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Potential Risks of Minoxidil in Pheochromocytoma and Paraganglioma: A Commentary on Safety Concerns and Mechanisms.Molecular neurobiology · 2025Article
- Article
- Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry.Therapeutic advances in medical oncology · 2024Article
- Telemedicine in Care of Sarcoma Patients beyond the COVID-19 Pandemic: Challenges and Opportunities.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 3 countries.
Michael J WagnerDepartment of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Cassandra HennessyDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Alicia BeeghlyDepartment of Medicine, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Benjamin FrenchDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Dimpy P ShahDepartment of Population Health Sciences, UT Health San Antonio, San Antonio, TX 78229, USA.
Sarah CroessmannDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA.
Diana Vilar-CompteDepartment of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0001-8564-8735
Erika Ruiz-GarciaDepartment of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.ORCID 0000-0002-0446-123X
Matthew InghamDepartment of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
Gary K SchwartzDepartment of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
Corrie A PainterBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Rashmi ChughDepartment of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Leslie FecherDepartment of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Cathleen ParkUniversity of Cincinnati Cancer Center, Cincinnati, OH 45267, USA.
Olga ZamulkoUniversity of Cincinnati Cancer Center, Cincinnati, OH 45267, USA.
Jonathan C TrentSylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.ORCID 0000-0001-6169-5238
Vivek SubbiahDepartment of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6064-6837
Ali Raza KhakiDepartment of Medicine, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0002-4655-4426
Lisa TachikiDepartment of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Elizabeth S NakasoneDepartment of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-5658-2551
Elizabeth T LoggersDepartment of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Chris LabakiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Renee Maria SalibyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Rana R McKayDepartment of Medicine, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Archana AjmeraDepartment of Medicine, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Elizabeth A GriffithsDepartment of Medicine, Roswell Park Comprehensive Cancer Center, University of Buffalo, Buffalo, NY 14203, USA.
Igor PuzanovDepartment of Medicine, Roswell Park Comprehensive Cancer Center, University of Buffalo, Buffalo, NY 14203, USA.
William D TapDepartment of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Clara HwangHenry Ford Cancer Institute, Detroit, MI 48202, USA.
Sheela TejwaniHenry Ford Cancer Institute, Detroit, MI 48202, USA.
Sachin R JhawarDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.ORCID 0000-0001-8604-4757
Brandon Hayes-LattinDivision of Hematology and Medical Oncology, Knight Cancer Institute at Oregon Health and Science University, Portland, OR 97239, USA.ORCID 0000-0002-4380-4573
Elizabeth Wulff-BurchfieldDepartment of Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA.ORCID 0000-0003-1474-7095
Anup KasiDepartment of Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA.
Daniel Y ReubenHollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Gayathri NagarajDivision of Hematology and Oncology, Loma Linda University School of Medicine, California, CA 92354, USA.ORCID 0000-0002-7586-6920
Monika JoshiDepartment of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA.ORCID 0000-0003-4286-8492
Hyma PolimeraDepartment of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA.
Amit A KulkarniMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0003-1042-8521
Khashayar EsfahaniSegal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC H4A 3J1, Canada.
Daniel H KwonUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California, CA 94117, USA.
Luca PaoluzziDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA.
Mehmet A BilenDepartment of Oncology, Emory University, Atlanta, GA 30322, USA.
Eric B DurbinDivision of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
Petros GrivasDepartment of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-3965-3394
Jeremy L WarnerDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA.
Elizabeth J DavisDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA.
COVID-19 and Cancer Consortium
University of Washington · USVanderbilt University · USVanderbilt University Medical Center · USColumbia University Irving Medical Center · USDana-Farber Cancer Institute · USHenry Ford Hospital · USInstituto Nacional de Cancerología · MXPenn State Milton S. Hershey Medical Center · USRoswell Park Comprehensive Cancer Center · USUniversity of California San Diego · USUniversity of Cincinnati · USUniversity of Kansas Medical Center · USUniversity of Michigan · USAlbert Einstein College of Medicine · USBroad Institute · USEmory University · USJewish General Hospital · CALoma Linda University · USMedical University of South Carolina · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTranslational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MUniversity of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3MNCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA177558NIH HHS P30 CA068485NIH HHS UL1 TR000445
Abstract
backgroundPatients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.
methodsWe performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.
resultsof 281 patients, 49% (
conclusionsPatients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
Indexed as
CCC19COVID-19sarcomaSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04354701ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.